培美曲塞联合顺铂与多西他赛联合顺铂治疗非小细胞肺癌的疗效比较

培美曲塞联合顺铂与多西他赛联合顺铂治疗非小细胞肺癌的疗
效比较
张波
【期刊名称】《癌症进展》
【年(卷),期】2015(000)006
【摘要】目的：探讨培美曲塞联合顺铂与多西他赛联合顺铂分别应用于晚期非小
细胞肺癌的临床疗效。

方法将68例晚期非小细胞肺癌患者随机分为培美曲塞组
（a组）及多西他赛组（b组），a组给予培美曲塞联合顺铂治疗，b组给予多西
他赛联合顺铂治疗。

治疗2个疗程结束后，将两组的疗效、不良反应及患者的生
活质量进行比较。

结果a组治疗后的总有效率为29.41%，疾病控制率为79.41%，b组的总有效率为23.53%，疾病控制率为70.59%，两组比较差异无统计学意义（P>0.05）；a组患者白细胞减少、贫血、血小板减少、恶心呕吐及肝功能异常
不良反应发生率分别是44.12%、17.65%、17.65%、29.41%、2.94%，b组患者白细胞减少、贫血、血小板减少、恶心呕吐及肝功能异常不良反应发生率分别为82.35%、58.82%、55.88%、76.47%、41.17%，均高于a组，差异有统计学意
义（P<0.05）；a组患者的生活质量各项评分均稍高于b组，但两组经统计分析，差异无统计学意义（P>0.05）。

结论培美曲塞联合顺铂应用于晚期非小细胞肺癌
的治疗效果与多西他赛联合顺铂无显著差别，但前者不良反应发生率小，应用更安全。

%Objective To investigate the clinical efficacy of pemetrexed combined with cisplatin and docetaxel combined with cisplatin as applied
in the treatment of advanced non-small cell lung cancer (NSCLC) patients. Meth-od A total of 68 patients with advanced NSCLC patients were
enrolled in this study, and were then randomized into either pemetrexed group (group A) or doceaxel group (group B), with administration of pemetrexed + cisplatin, or docetaxel + cisplatin, respectively. After 2 cycles of treatment, the curative effect, adverse reactions and quality of life of patients in both groups were compared. Result An overall response rate (ORR) of 29.41%, and disease con-trol rate (DCR) of 79.41% were observed in group A, and the ORR was 23.53%, and DCR was 70.59% in group B, with no significant inter-group differences found (P > 0.05); The incidences of adverse reactions including leukope-nia, anemia, thrombocytopenia, nausea and vomiting, and abnormal liver function (44.12%, 17.65%, 17.65%, 29.41%, and 2.94%, respectively) in group A were significantly lower than that of group B (82.35%, 58.82%, 55.88%, 76.47%, and 41.17%, respectively) (P < 0.05). The quality of life (QOL) scores were slightly higher in group A than that of group B, but there was no significant differences found through statistical analysis (P > 0.05). Conclusion Pemetrexed in combination with cisplatin is similar with docetaxel combined with cisplatin in respect of efficacy for advanced NSCLC, while the incidence of adverse reactions of the former is lower, making it a regimen with
better&nbsp;safety.
【总页数】4页(P650-653)
【作者】张波
【作者单位】本溪钢铁集团总医院呼吸内科，辽宁本溪117000
【正文语种】中文
【中图分类】R734.2
【相关文献】
1.培美曲塞联合顺铂与多西他赛联合顺铂治疗晚期非小细胞肺癌的临床疗效比较[J], 李雅冰
2.培美曲塞联合顺铂与多西他赛联合顺铂治疗晚期非小细胞肺癌的临床疗效比较观察 [J], 蒋安亮
3.培美曲塞联合顺铂与多西他赛联合顺铂治疗晚期非小细胞肺癌的临床疗效比较[J], 尚瑞国
4.培美曲塞联合顺铂与多西他赛联合顺铂治疗晚期非小细胞肺癌的疗效比较 [J], 熊慧如;尤传文;陆锡艳;刘金平
5.培美曲塞联合顺铂与多西他赛联合顺铂治疗非小细胞肺癌的效果和安全性 [J], 张庆超
因版权原因，仅展示原文概要，查看原文内容请购买。